Retatrutide, one of the most buzzed about peptides of the moment, also known simply as “reta” or incorrectly as “ratatouille,” is Eli Lilly’s investigational triple-hormone receptor agonist for weight management. This triple receptor agonist is currently the subject of a regulatory dispute with the FDA about whether it should be classified as a small-molecule drug or a biologic. This classification has implications for its compounding eligibility since biologics are ineligible for traditional compounding under the FD&C Act, which we’ll explore in this post.
Does the FDA Consider Retatrutide to be a Biologic?
First, it is critical to understand the determining characteristics of what constitutes a biologic versus a protein. A biologic (or biological product) is a category of medical products regulated by agencies like the U.S. Food and Drug Administration (FDA). They are produced by utilizing living systems—such as microorganisms, plant cells, or animal cells. Distinct from “small molecule” drugs (like penicillin or ibuprofen), biologics are large and structurally intricate compounds.
Proteins are the building blocks of many biologic drugs (like growth hormones) and are synthesized in a lab using bacteria or yeast. In short, all therapeutic protein-based drugs are biologics, but not all biologics are strictly proteins.
Eli Lilly’s Stance
Eli Lilly asserts that retatrutide falls under the regulatory definition of a protein (i.e., a biologic) as it contains a total of 41 amino acid residues. However, the FDA argued that a biologic must contain a sequence of more than 40 alpha amino acids and concluded that retatrutide only has 40, along with one non-alpha amino acid, ADO.1 The agency also rejected Lilly’s other argument that the molecule is analogous to a protein and reaffirmed its position that retatrutide is a small-molecule drug and not a biologic.
Lilly continues to challenge the classification and maintains that retatrutide should be regulated as a biologic, but for now, the FDA still views it as a small-molecule drug.
Are you a prescriber looking for compounded medical solutions?
Please complete our new account form.
Retatrutide Compounding Eligibility
Regardless of its eventual classification, retatrutide is not yet FDA-approved, therefore it is ineligible for compounding. The FDA has explicitly stated that retatrutide cannot be used in compounding under federal law since it’s not a component of an FDA-approved drug, and the agency has issued numerous warning letters in 2026 to companies that have marketed this unapproved new drug.
The net-net: unless retatrutide is approved, nothing has changed for compounding pharmacies since investigational new drugs may not be compounded outside of authorized clinical trials nor distributed to patients outside of regulated research or emergency/expanded access pathways.2
- Approved as a biologic: Should retatrutide be approved as a biologic as a result of future legal challenges, then it would remain prohibited for compounding since biological products cannot be compounded, even under the typical exemptions for small-molecule drugs, such as drug shortages.
- Approved as a small-molecule drug: If retatrutide is ultimately approved by the FDA as a small-molecule drug instead of a biologic, there could be potential for compounding during drug shortages or other qualifying circumstances as specified under 503A or 503B.
Research Use Only Peptides
Although retatrutide isn’t FDA-approved, some patients have seen the results of its clinical trials3 and managed to obtain research use only (RUO) retatrutide, despite the safety concerns. One news investigation found that one vial marketed as retatrutide contained phenylacetic acid, and other tests identified 13 bacteria colonies. Although these findings involved only one particular sample, they show the risks associated with obtaining peptides from unregulated suppliers.
These concerns aren’t new. The FDA has previously warned that RUO GLP-1s are often of unknown quality and have not undergone review for safety or effectiveness. When evidently pressed upon by patients, prescribers should direct patients to obtain FDA-approved drugs and peptides through licensed pharmacies. They should further explain that this requires a valid, patient-specific prescription, rather than risk exposure to mislabeled, contaminated, or incorrectly formulated products.
Other Weight Management Options from VLS Pharmacy
Prescribers looking for retatrutide alternatives may consider other weight management therapies, including peptide-based options where appropriate. Treatment selection should account for each individual patient’s medical history, weight management goals, and their response to therapy. VLS Pharmacy offers a range of weight management treatment options and peptide therapies to support prescribers in identifying individualized approaches for specific patients.
Please comment below with any thoughts or questions.
Reach out to our team to learn about best practices and to partner with our experts on custom compounded medications for your patients. All medications from VLS Pharmacy and New Drug Loft are prepared in a lab that follows safety and quality standards per our status as a 503A pharmacy. This is not medical advice and should not be construed as such.
References
- Chang T. Eli Lilly & Co. v. Kennedy. Food and Drug Law Institute. Published June 24, 2026. Accessed November 4, 2026. https://www.fdli.org/2026/06/eli-lilly-v-kennedy/
- Chapter 30: Compounding for clinical and investigational studies. In: The Art, Science, and Technology of Pharmaceutical Compounding. 6th ed. American Pharmacists Association; 2020. doi:10.21019/9781582123578.ch30
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. Published online 2026. doi:10.1056/NEJMoa2604169
Read More…
- Tour our pharmacy
- What makes VLS Pharmacy different from other compounding pharmacies
- It’s never been easier to submit your prescriptions! Place your order today
DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE. The information provided on this website is for general informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Nothing on this website should be construed as a substitute for professional medical advice from a qualified healthcare provider. Always consult your physician or other qualified healthcare professional regarding any medical condition, treatment, medication, or health concern. Never disregard or delay seeking professional medical advice because of information found on this website. While we strive to provide accurate and current information, VLS Pharmacy and New Drug Loft make no representations or warranties regarding the completeness, accuracy, or reliability of any content on this website. By using this website, you acknowledge that any reliance on the information provided is solely at your own risk.
